PFE Q4 2025 Earnings Analysis

And I'm Jordan. Before we dive in, I want to make sure our listeners know that this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.

The headline numbers tell a story of resilience, Alex. Pfizer posted $62.6 billion in full-year revenue versus $63.6 billion last year - that's a 2% operational decline. But here's the key detail: when you strip out their COVID products, they actually grew operational revenue by 6%.

Even better news there. Adjusted earnings per share came in at $3.22 versus $3.11 last year, beating expectations. They expanded gross margins to 76%, and their recently launched and acquired products - which is really their growth engine - delivered over $10 billion in revenue with 14% operational growth.

Pretty significant. COVID products dropped about 40% operationally year-over-year in Q4. But Alex, this is actually old news at this point. What's more interesting is how well they're managing through it. Their non-COVID business grew 9% in the quarter, driven by products like Abrysvo, Eliquis, Prevnar, and the Vyndaqel family.

They're guiding for $59.5 to $62.5 billion in revenue and $2.80 to $3.00 in adjusted EPS for 2026. What's notable is they're expecting COVID revenues to drop to about $5 billion, and they're anticipating $1.5 billion in revenue compression from generic competition. But even with those headwinds, they expect their core business excluding COVID and loss-of-exclusivity products to grow about 4% operationally.

Absolutely, Alex. They announced results from their VESPER-3 study for PF-3944, which is their investigational obesity treatment. And the key differentiator here is that it's designed for monthly dosing instead of weekly like current GLP-1 drugs.

The data showed 10-12% placebo-adjusted weight loss at 28 weeks for their planned phase 3 doses. But here's what's really interesting - their modeling suggests the higher dose they're planning could deliver nearly 16% weight loss. And importantly, they didn't see a weight loss plateau at 28 weeks, suggesting patients could lose even more weight over time.

It's competitive with existing weekly GLP-1s like Ozempic and Wegovy, but the monthly dosing is the real differentiator. During the Q&A, their commercial team emphasized that reducing from four injections per month to just one could be a major advantage for patient compliance and switching existing patients to their therapy.

The safety profile looked similar to other GLP-1 drugs. They saw mostly mild to moderate GI side effects, and importantly, discontinuation rates were reasonable. What's encouraging is that they didn't see a spike in discontinuations when patients switched from weekly to monthly dosing, despite the four-fold higher dose.

They've really been positioning for what CEO Albert Bourla called "industry-leading growth towards the end of the decade." They've made major acquisitions - Seagen for oncology, Metsera for obesity, and Biohaven for migraine treatments. The integration seems to be going well, especially Seagen, where they're expanding indications and starting new phase 3 trials.

Right, but Pfizer seems to be taking a very practical approach. They're expanding to over 1,200 GPUs over the next two years, and they're embedding AI across R&D, manufacturing, and commercial operations. What I found interesting was their claim that AI is already helping them achieve cost savings without impacting their top-line performance. They're using it for everything from drug discovery to optimizing their field force productivity.

They recorded about $4.4 billion in non-cash impairments in Q4, basically writing down assets they've decided not to pursue further. But CFO Dave Denton emphasized this reflects their focus on high-impact medicines. Interestingly, one asset they deprioritized was actually because another asset in their portfolio - PADCEV from the Seagen acquisition - is performing so well that it makes the other asset less valuable.

They returned $9.8 billion to shareholders via dividends in 2025 and maintain their commitment to the dividend. With about $7 billion in business development capacity, they seem positioned for more strategic acquisitions. Though they're being disciplined given the upcoming patent cliff challenges.

Several key catalysts. They're starting about 20 pivotal studies this year, including 10 in their obesity portfolio. They're expecting major readouts including their Lyme disease vaccine, which could be first-in-class, and several oncology programs. The obesity program is really the big story though - if the phase 3 data holds up, they could have approvals starting in 2028.

The patent cliff is real. Products like Vyndaqel lose exclusivity in 2028, and management was pretty clear they're not expecting any patent extensions there. They're also navigating a competitive obesity market where timing will matter a lot. But overall, the underlying business fundamentals look solid, and they seem to be executing well on their strategic transformation.

This feels like a company successfully managing through a transition period. The COVID tailwinds are gone, the patent cliff is coming, but they're building what could be a very strong growth platform for the late 2020s. The obesity data today was genuinely impressive, and if they can execute on their broader pipeline, they could emerge from this challenging period in a much stronger position.

Exactly. And one final reminder for our listeners - everything we've discussed today is AI-generated analysis for educational purposes. Past performance doesn't guarantee future results. Please do your own due diligence before making any investment decisions.

See you next time! ---